Startups
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.
Overview
Location
Czechia, Prague
Employees
201-500
Total raised
$316.9M
Founded date
2010
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 28
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 12, 2024 | The Hidden Struggles of X-Linked Hypophosphatemia: A Call for Awareness and Action | X-linked hypophosphatemia (XLH) is a name that may not ring a bell for many. Yet, for those affected, it’s a daily battle. A recent analysis from the XLH Disease Monitoring Program (DMP) sheds light on the harsh realities faced by adults li... |
| Sep 9, 2024 | More space for healthtech start-ups on the Novartis Campus | Digitalisation is one of the megatrends in the healthcare sector. It not only promises greater efficiency, but also new possibilities in diagnostics and therapeutics. As this field requires expertise that traditional healthcare companies o... |
| Oct 18, 2022 | SOTIO to Present the AURELIO-04 Phase 2 Study Design and Findings from BOXR Research at the SITC Annual Meeting | BASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will share two poster presentations, namely the Phase 2 AURELIO-0... |
| Sep 14, 2022 | SOTIO Bolsters Leadership Team with Appointment of Martin Steegmaier as Chief Scientific Officer | PRAGUE, Czech Republic, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced the appointment of Martin Steegmaier, Ph.D., MBA, as chief scientific officer. Martin Steegmaie... |
| Sep 12, 2022 | SOTIO Strengthens Management Team with Appointment of Robyn Hunter as Chief Financial Officer | CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announces the appointment of Robyn Hunter as chief financial officer. Ms. Hunter is an accomplished CFO who bri... |
| Jul 26, 2022 | SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab) | AURELIO-04 will enroll up to 320 patients and test the combination in multiple solid tumor indications Clinical collaborator, MSD (Merck & Co., Inc., Rahway, NJ, USA), will supply KEYTRUDA for the study that is being conducted in Europe... |
| Apr 27, 2022 | Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual Meeting | SOTIO will share interim safety and efficacy results from SOTIO’s AURELIO-03 study on Saturday, June 4 AURELIO-03 is a Phase 1/1b dose escalation study of the interleukin-15 superagonist SOT101 as monotherapy and in combination with pembrol... |
| Apr 26, 2022 | SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer | CLAUDIO-01 is the first-in-human trial of SOT102, a CLDN18.2 (Claudin 18.2) targeting antibody-drug conjugate (ADC) The trial will enroll up to 109 patients with gastric and pancreatic cancer PRAGUE, Czech Republic, April 26, 2022 (GLOBE NE... |
| Apr 12, 2022 | Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting | PRAGUE, Czech Republic and BASEL, Switzerland and CAMBRIDGE, Mass, April 12, 2022 (GLOBE NEWSWIRE) -- Interim Results of the Phase 1 AURELIO-03 study of SOT101 in combination with pembrolizumab for patients with advanced metastatic tumors w... |
Show more
Reviews 0
FAQ about SOTIO
When was SOTIO founded?
SOTIO was founded in 2010.
How much funding has SOTIO raised?
SOTIO has raised $316.9M in total across 1 funding round.
What has the press written about SOTIO?
Parsers VC has collected 28 articles mentioning SOTIO, among them “The Hidden Struggles of X-Linked Hypophosphatemia: A Call for Awareness and Action” (Sep 12, 2024) and “More space for healthtech start-ups on the Novartis Campus” (Sep 9, 2024).
Is SOTIO still active?
Yes, SOTIO is active; its latest activity on Parsers VC dates from Jan 6, 2025.